POLA-R-CHP

DRUG4 trials

Sponsors

Fudan University, Sun Yat-sen University, The First Affiliated Hospital of Soochow University

Conditions

DLBCLDiffuse Large B Cell Lymphoma (DLBCL)Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Transformed Lymphoma

Phase 1

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Not yet recruitingNCT07398638

Sun Yat-sen UniversityDiffuse Large B Cell Lymphoma (DLBCL)

Start: 2026-02-28End: 2031-02-28Target: 122Updated: 2026-02-10

Phase 2

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

RecruitingNCT06743945

Fudan UniversityTransformed Lymphoma

Start: 2025-02-17End: 2029-12-31Target: 20Updated: 2025-02-25

Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

RecruitingNCT07499271

The First Affiliated Hospital of Soochow UniversityDiffuse Large B-Cell Lymphoma (DLBCL)

Start: 2026-01-01End: 2027-12-31Target: 35Updated: 2026-03-30

Unknown Phase

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

RecruitingNCT07070648

Fudan UniversityDiffuse Large B-Cell Lymphoma, DLBCL

Start: 2025-05-09End: 2027-12-30Target: 300Updated: 2025-07-17